{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:08:40Z","timestamp":1790348920056,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.12.012","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T09:25:22Z","timestamp":1577093122000},"page":"1363-1369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["The potential impact of dengue vaccination with, and without, pre-vaccination screening"],"prefix":"10.1016","volume":"38","author":[{"given":"Laurent","family":"Coudeville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Baurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-0593","authenticated-orcid":false,"given":"Donald S.","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.012_b0005","doi-asserted-by":"crossref","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination","volume":"7","author":"Beatty","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.12.012_b0010","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.12.012_b0015","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman","year":"2013","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2019.12.012_b0020","doi-asserted-by":"crossref","first-page":"719","DOI":"10.7150\/ijms.5037","article-title":"Inhibition of dengue virus entry into target cells using synthetic antiviral peptides","volume":"10","author":"Alhoot","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.vaccine.2019.12.012_b0025","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11948-014-9557-5","article-title":"Factors influencing stakeholders attitudes toward genetically modified aedes mosquito","volume":"21","author":"Amin","year":"2015","journal-title":"Sci Eng Ethics"},{"key":"10.1016\/j.vaccine.2019.12.012_b0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/0972-9062.184837","article-title":"Spatial distribution and insecticide susceptibility status of Aedes aegypti and Aedes albopictus in dengue affected urban areas of Rawalpindi, Pakistan","volume":"53","author":"Arslan","year":"2016","journal-title":"J Vector Borne Dis"},{"key":"10.1016\/j.vaccine.2019.12.012_b0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14787210.2017.1248405","article-title":"Current management of severe dengue infection","volume":"15","author":"Lee","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.vaccine.2019.12.012_b0040","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1473-3099(16)00146-8","article-title":"The global economic burden of dengue: a systematic analysis","volume":"16","author":"Shepard","year":"2016","journal-title":"Lancet Infectious Diseases"},{"key":"10.1016\/j.vaccine.2019.12.012_b0045","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.012_b0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.012_b0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.012_b0060","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029462","article-title":"Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine","volume":"10","author":"Guy","year":"2018","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"10.1016\/j.vaccine.2019.12.012_b0065","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1016\/j.vaccine.2016.08.050","article-title":"Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine","volume":"34","author":"Coudeville","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.012_b0070","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.aaf9590","article-title":"Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.12.012_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002181","article-title":"The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study","volume":"13","author":"Flasche","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2019.12.012_b0080","article-title":"Assessment of benefits and risks associated with dengue vaccination at the individual and population levels: a dynamic modeling approach","volume":"1\u201311","author":"Coudeville","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.12.012_b0085","first-page":"329","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, April 2018 \u2013 conclusions and recommendations","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2019.12.012_b0090","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1016\/j.vaccine.2019.07.016","article-title":"Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report","volume":"37","author":"Wilder-Smith","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.012_b0095","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2017.11.064","article-title":"Cost-effectiveness of dengue vaccination in ten endemic countries","volume":"36","author":"Zeng","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.012_b0100","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz078","article-title":"Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection","author":"Bonaparte","year":"2019","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2019.12.012_b0105","unstructured":"World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE); 2019."},{"key":"10.1016\/j.vaccine.2019.12.012_b0110","doi-asserted-by":"crossref","DOI":"10.1093\/trstmh\/try057","article-title":"Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study","author":"Turner","year":"2018","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.12.012_b0115","series-title":"Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure","author":"Espana","year":"2018"},{"key":"10.1016\/j.vaccine.2019.12.012_b0120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1590\/0037-8682-0145-2015","article-title":"Trends and factors associated with dengue mortality and fatality in Brazil","volume":"48","author":"Paixao","year":"2015","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.vaccine.2019.12.012_b0125","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.vaccine.2018.01.007","article-title":"Estimation of expected dengue seroprevalence from passive epidemiological surveillance systems in selected areas of Argentina: A proxy to evaluate the applicability of dengue vaccination","volume":"36","author":"Orellano","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:38:23Z","timestamp":1759401503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19316548"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.012","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential impact of dengue vaccination with, and without, pre-vaccination screening","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}